Synthetic progesterone used in contraception drugs (progestins) can promote breast cancer growth but the mechanisms involved are unknown. Moreover, it remains unclear whether cytoplasmic interactions between the progesterone receptor (PR) and estrogen receptor alpha (ERĮ) is required for PR activation. In this study, we used a Chromatin immunoprecipitation studies demonstrated that MPA triggered binding of ERĮ and PR to the CCND1 and MYC promoters. Interestingly, blockade or RNAimediated silencing of ERĮ inhibited ERĮ, but not PR binding to both regulatory sequences, indicating that an interaction between ERĮ and PR at these sites is necessary for MPA-induced gene expression and cell proliferation. We confirmed that nuclear colocalization of both receptors also occurred in human breast cancer samples. Together, our findings argued that ERĮ-PR association on target gene promoters is essential for progestin-induced cell proliferation.
INTRODUCTION
Breast cancer is the most frequently diagnosed cancer and a leading cause of cancer death in women worldwide (1) . Although most of the evidence suggests estrogens as the major etiological factors in breast cancer (2) , experimental and epidemiological evidence, reviewed recently (3) (4) (5) , also points to the involvement of progesterone receptors (PR) in breast cancer development and progression. However, the mechanisms by which PR participate in tumor growth are not yet well understood. Considering that PR is usually used as a marker of estrogen receptor alpha (ERĮ) functionality (6) , it may be intuitive to think that there is a sequential effect on ERĮ inducing PR expression. It has been reported that an early cytoplasmic interaction between ERĮ and PR isoform B Using a progestin-dependent murine mammary carcinoma, C4-HD (10) and the human T47D breast cancer cells, which are also stimulated by progestins (11, 12), we demonstrate that a genomic interaction between ERĮ and PR is essential for progestininduced gene expression and tumor cell proliferation. Chromatin immunoprecipitation (ChIP) using T47D cells, confirms that PR is activated in the absence of ERĮ. However, the presence of both activated receptors at the MYC or CYCLIN D1 (CCND1) promoters is required to trigger gene expression and cell proliferation. Moreover, the nuclear colocalization of both receptors in human breast cancer samples suggests that a genomic interaction between activated ERĮ and PR may be a common event in breast cancer growth. Secondary antibodies were obtained from Vector Labs.
MATERIALS AND METHODS

Antibodies. PR (C-
Reagents. DAPI, medroxyprogesterone acetate (MPA, 10nM) and RU-38486 (RU, 10nM) were purchased from Sigma. ICI 182.780 (ICI) was a gift from AstraZeneca.
Animals. Two-month-old virgin female BALB/c mice (IByME-Animal Facility) were used. Animal care and manipulation were in agreement with institutional and reference guidelines (13).
In vivo experiments. Depot MPA (20mg) was used as a progestin. C4-HD tumors were subcutaneously (s.c.) transplanted into MPA-treated BALB/c mice as previously Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on March 6, 2012; DOI: 10.1158/0008-5472. Immunohistochemistry. Sections of formalin-fixed, paraffin-embedded tissues were reacted with different antibodies using the avidin-biotin peroxidase complex technique (Vector Lab) and counterstained with hematoxylin (17). Positive cells were counted in 10 high-power fields (HPFs, 1000X) of each section, and expressed as the mean ± SEM of the percentage of the ratios between the number of events and the cell number/HPF.
Immunofluorescence and co-localization. Tumors. Frozen tumor sections were fixed in formalin, post-fixed in 70% ethanol, blocked, and incubated with the primary antibodies and FITC/TX-conjugated secondary antibodies, and counterstained with DAPI as described previously (18). Images were obtained using a Nikon Eclipse E800 Confocal Microscope and Nikon DS-U1 with ACT-2U software. Cells. Cultures growing on chamber slides were fixed in 70% ethanol, and processed as described previously (18). To quantify nuclear co-localization of PR and ERĮ, we used the Pearson's correlation coefficient (R r ). Nuclei (200) of selected samples were analyzed by using PSC Colocalization plug-in (ImageJ-NIH; 19). R r ranges between í1 (perfect negative correlation) to +1 (perfect positive correlation) with 0 meaning no correlation.
Tumor and cell extracts. Tumors were homogenized and processed to obtain nuclear purified fractions (20) and total cell extracts prepared using M-PER mammalian protein extraction reagent (Pierce). Nuclear cell culture extracts were obtained and proteins quantified as described previously (21). Immunoprecipitation (IP) assays. Nuclear extracts containing 0.5-1 mg of proteins were subjected to IP using 2 μg of PR or ERĮ antibodies, and rocked overnight at 4°C.
The immunocomplexes were then captured by adding protein A-agarose (Santa Cruz), processed as described (18) and subjected to western blots.
Western blots. Tumor, cell extracts (100 μg proteins/lane) or IP proteins were separated on discontinuous polyacrylamide gels and detected as previously described (20).
Activation of reporter genes. The PRE-Luc vector used was a gift from Dr. C. Gardmo (22) and assays were performed as described previously (18).
RNA preparation and real-time quantitative PCR (qPCR).
Total RNA was isolated from cultures with TRIzol Reagent (Invitrogen) and converted to cDNA as described previously (18). Specific oligos for human MYC (NM_002467.4) and CCND1 (NM_053056.2) were designed using Primer-Blast (NCBI ; Table S1 ). GAPDH (NM_002046.3) expression was used as a normalization control. Data from three experiments were combined to determine gene expression changes using 2 (-¨Ct) formula.
A melting curve was generated for every run to confirm assay specificity.
ChIP and sequential ChIP assays. After treatment, cells were fixed with 1% PFA for 30 min; ChIP assays performed as recommended by Diagenode using the HighCell# ChIP kit. Specific oligos for human CCND1 and MYC promoters were designed using PrimerBlast (NCBI; Table S1 ). The data from each IP (IgG, PR and ERĮ) was normalized to the were repeated at least three times. Significant differences between control and treated cells were indicated with asterisk (*, p<0.05; **, p<0.01; ***, p<0.001).
RESULTS
1) ERĮ play a key role in C4-HD tumor growth in vivo.
We have previously shown that C4-HD tumors, that express ERĮ and PR, grow in MPA-or progesterone (Pg)-treated female mice (10) and that the blockade of PR induces complete tumor regression (23). This experimental system provided an opportunity to explore the role of ERĮ in progestin-induced tumor growth by using the pure antiestrogen FUL. Surprisingly, FUL induced a complete regression of tumors growing in the presence of MPA (Fig. 1A) , and this was associated with a decrease in both PR isoforms and ERĮ expression, as evaluated by Western blot (Fig. 1B) and immunohistochemistry (Fig. 1C) . Expression of ERĮ after MPA withdrawal was negligible, however, a significant increase in PR was observed after MPA removal, suggesting that, in the progestin-dependent C4-HD tumor, while MPA downregulates PR expression, it may be required to maintain high levels of ERĮ expression in vivo (Fig. 1C) . Moreover, activated ERĮ (pSer167 and pSer118 ERĮ) was also high in MPA-treated tumors ( Supplementary   Fig. S1A ). FUL-induced tumor regression was associated with a cytostatic effect as
shown by a decrease in the mitotic index (Ki67 quantification, Supplementary Fig. S1B ), and in the expression of two progestin-regulated proteins, CCND1 and MYC (Fig. 1C ).
In addition, in FUL-treated tumors, an increase in apoptosis ( Supplementary Fig. S1B ), associated with a decrease in BCL/XL and an increase in BAX and AIF (Supplementary of ERĮ (6 h), while high levels of PR were still detected after 24 h ( Supplementary Fig.   S2C ), indicating that the blockade of MPA-induced cell proliferation by ICI was not associated with PR downregulation.
An increase in both nuclear ERĮ and PR immunoreactivity and nuclear colocalization was observed in MPA-treated cells, (Fig. 2B) . A time course analysis of the interaction revealed that they start co-localizing as early as 5 min after MPA incubation with a decrease after 1 h (Fig. 2B ). In cells treated for 30 min with MPA+ICI, there was a decrease in nuclear and an increase in cytosolic ERĮ staining ( Fig. 2C left, arrows). These results suggest that ICI disrupts the molecular interaction induced by MPA. Similar incubations were performed with the corresponding phospho-receptor antibodies.
Phospho-Ser118 ERĮ staining increased after 30 min of MPA treatment and co-localized with pSer162 PR B (Fig. 2C , middle) or pSer294 PR (Fig. 2C, right) . These observations suggest that ERĮ and PR may be forming part of the same complexes in their active state (24). No cytosolic or membrane co-localization of PR and ERĮ was observed in MPAtreated cells and no staining was observed in hormone-receptor-negative murine LM3 (25) breast cancer cells (data not shown). Moreover, using frozen samples from C4-HD tumors growing in MPA-treated mice, we confirmed the nuclear co-localization between PR/ERĮ in vivo (Fig. 2D, left) . Finally, we corroborated the interaction between both receptors by co-IP assays using nuclear extracts from MPA-treated C4-HD tumors.
Proteins were immunoprecipitated with two different PR or ERĮ antibodies and blotted accordingly ( Fig. 2D, right) . These results suggest that both PR isoforms can participate in a nuclear complex with ERĮ. 
3) Nuclear interaction between ERĮ and PR in human breast cancer.
To investigate whether the co-localization between ERĮ and PR was unique for our murine model, we evaluated the expression of ERĮ, PR and pPR in 15 frozen breast cancer samples. In 4 of them (two ductal and two lobular carcinomas) we found a high degree of nuclear co-localization (Fig. 3A) . We found a mild co-localization in three samples and a sporadic co-localization in other two samples. No staining was observed in receptor negative tumors (Fig. 3B ). Co-IP assays performed using purified nuclear extracts from 2 positive samples and a negative control confirmed the nuclear interaction between ERĮ and PR ( Fig. 3C ). These results suggest that the interaction between ERĮ and PR has an important and yet unexplored role in human breast cancer.
4) ERĮ and PR interaction in the nuclei of progestin-stimulated T47D cells is necessary to induce cell proliferation.
To further investigate the role of ERĮ in MPA-induced cell proliferation we used T47D cells. MPA increased the nuclear co-localization between ERĮ and PR during the first 5-10 min, and then a decrease was observed after 30 min of treatment ( We observed a significant increase in pSer294 PR (p<0.01) and in ERĮ (p<0.05) or in total PR (p<0.01) respectively, as compared with IPs from untreated cells (Fig. 4B) . antibodies ( Supplementary Fig. S3C ). These results demonstrate that both PR isoforms interact with ERĮ in the cell nuclei of human progestin-treated cells. We then explored the role of ERĮ in MPA-driven proliferative responses. ICI (0.1 and 1 ȝM) dramatically inhibited DNA-synthesis to levels similar to those of the antiprogestin RU (Fig. 4C) .
Additionally, we used two different siRNAs that decreased ERĮ expression (Fig. 4D, left) , and also inhibited MPA-induced [ 3 H]-thymidine uptake (Fig. 4D, right) . To further understand the role of ERĮ mediating MPA transcriptional activities, we evaluated the effect of ICI on the activation of a reporter luciferase assay controlled by the progesterone response element (PRE) sequence in T47D cells. ICI inhibited MPAinduced PRE-luc expression (Fig. 6A) , and induced the downregulation of ERĮ, while PR was still expressed even after 48 h of ICI incubation ( Supplementary Fig. S3D ).
5) The inhibition of ERĮ expression prevents MPA-induced
Moreover, MPA induced a higher PRE-luc activity in MDA-MB-231 cells stably transfected with PR B , when they were co-transfected with ERĮ ( Supplementary Fig.   S5 ).These results strongly suggest a role for the PR/ERĮ complexes in the regulatory elements of MPA-regulated genes. To confirm the binding of both receptors to the same promoter regions we used ChIP analysis on CCND1 and MYC regulatory sequences. In Figure 6B we show a schematic representation of both gene promoters, highlighting the PRE and estrogen response element (ERE) sites in each case, as well as the primers used in ChIP/qPCR analysis. Cells were incubated with MPA (10 min) and the chromatin subjected to IP with PR-or ERĮ-specific antibodies. DNA fragments were amplified by qPCR with three pairs of primers for each gene, previously used by others to report PR binding to those sequences (31, 33, 34; Fig. 6B ). The recruitment of ERĮ and PR to the sites at +5-6 Kb (ChIP primers C) was used as a negative control of receptor binding ( 
antibodies were used in the first IP, and ERĮ or PR antibodies in the sequential ChIP (reChIP). qPCR analysis clearly showed that PR and ERĮ co-occupy the CCND1 and MYC promoters after 10 min of MPA stimulation (Figs. 6C and 6D, right panels) . These findings suggest that progestins induce the assembly of PR/ERĮ protein complexes at both promoters to control its transcriptional activation in breast cancer cells.
To further understand the molecular mechanism driving these effects, we evaluated ERĮ and PR binding to these regulatory sequences when we inhibited ERĮ. PR binding to both gene promoters was unaffected by the presence of ICI (Fig. 7A ) or siRNA to ERĮ (Fig. 7B ), while they did prevent ERĮ binding. These data indicate that both proteins need to interact at the CCND1 and MYC promoters to induce gene transcription and cell proliferation, supporting our hypothesis that the presence of ERĮ at those promoters is required to induce PR-mediated gene expression.
DISCUSSION
In this study we have demonstrated that a progestin can induce a direct and transient nuclear interaction between ERĮ and both PR isoforms at the promoters of two progestin responsive proto-oncogenes, namely CCND1 and MYC. Moreover, this activity can have dramatic effects on breast cancer cell proliferation and seems to be dependent on ERĮ actions, as its inhibition with ICI induced complete regression of C4-HD tumors growing in the presence of the progestin. Thus, our results suggest that a combined treatment with antiestrogens and antiprogestins can be beneficial to breast cancer patients.
As it has previously been reported (35), the co-treatment with antiprogestins plus selective estrogen receptor modulators (SERMs) may have an additive effect. Moreover, 
MPA-independent murine mammary carcinomas, C4-HI, respond better to a combination of tamoxifen and mifepristone than to both single agents (36).
We confirmed our observations in the murine model, using T47D cells where the inhibition of ERĮ activity resulted in a complete blockade of MPA-dependent MYC and CCDN1 gene transcription and cell proliferation. The fact that progestins exerted growth inhibitory effects on MDA-MB-231 cells stably transfected with PR (37) but stimulated cell proliferation in models that co-express ERĮ and PR (11, 12, 15, 16, 38), also suggests that both receptors cooperate to trigger cell proliferation. In this regard, it is known that the human MYC gene promoter contains a functional PRE that mediates the binding of activated PR (18, 31, 39) and we also identified other consensus PRE halfsites (40) that might also bind PR (Fig. 6B) . Moreover, it has recently been reported that ERE half-sites at the MYC proximal promoter (Fig. 6B) are not responsive to estrogens (41). It may be possible that after progestin treatment these sites might also bind ERĮ in complexes with PR. In addition, we have recently shown in T47D cells that MPA induces the binding of PR, transcription factors (TF), such as STAT5, and nuclear tyrosine kinase receptors (RTKs), such as FGFR-2, to the same regions of the MYC promoter (18). The results reported herein indicate that activated ERĮ could be present in the same multimeric protein complexes as supported by NoShift EMSA assays (18; Fig. 7C -iii-) .
The regulation of human CCND1 by progestins may be more complicated, as no canonical PRE sites have been described in its promoter and accordingly, it has been suggested that PR regulates CCND1 expression by non-genomic mechanisms (7, 9, 34).
The two models of cytoplasmic signaling pathways activated by Pg are shown in Figure   7C . Model -i-proposes that an early interaction between ERĮ and PR B is necessary for c- Fig. 7C -v-) .
However, it has been recently demonstrated that PR may have genomic effects at the CCND1 promoter (34, 44), even as a co-activator of STAT3 (26; Fig. 7C -iv-) . In this study, we showed for the first time that PR and ERĮ share the same progestins-sensitive regions at CCND1 and MYC promoters (Fig. 7C -iii-) . Interestingly, we found distinct consensus PRE half-sites (40) at the CCND1 promoter ( Finally, in this study we also showed that both receptors interact in the nuclei of selected human breast cancer samples, suggesting that ligand-independent hormone receptor activation may also be implicated in breast cancer tumor growth in patients.
Thus, it is possible to speculate that patients showing higher levels of PR/ERĮ colocalization may have a better response to a combined antiprogestin-antiestrogen therapy. Gutkind's Laboratory.
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